62 results
6-K
EX-99.1
SCNI
Scinai Immunotherapeutics Ltd
25 Apr 24
Report of Foreign Private Issuer
4:00pm
for Multidisciplinary Sciences UMG Head of Department Covering discovery and initial characterization of NanoAbs aimed at predefined list of molecular targets. Designed … due to massive libraries De - risked pipeline development leveraging approved mAb targets Hyper - thermostable = longer shelf life, easier storage
6-K
EX-99.1
SCNI
Scinai Immunotherapeutics Ltd
16 Apr 24
Report of Foreign Private Issuer
5:27pm
targets in psoriasis Schön MP and Wilsmann - Theis D: Current developments and perspectives in psoriasis . J Dtsch Dermatol Ges 2023;21(4):363 - 73
CLICK … and initial characterization of NanoAbs aimed at predefined list of molecular targets. Designed to create significant clinical and commercial
F-3
SCNI
Scinai Immunotherapeutics Ltd
30 Jan 24
Shelf registration (foreign)
4:19pm
and aRCA, the “MPG/UMG Agreements”) with MPG and UMG covering the discovery, selection and characterization of NanoAbs for up to nine molecular targets … viability. We believe that since these are clinical validated targets, we can develop NanoAb treatments with reduced risk and cost and accelerate
6-K
EX-99.1
SCNI
Scinai Immunotherapeutics Ltd
18 Jan 24
Report of Foreign Private Issuer
11:50am
aimed at predefined list of molecular targets. Designed to create significant clinical and commercial advantages. Scinai brings… MAX PLANCK , UMG … mammalian cells Quicker antibody discovery and optimization due to massive libraries De - risked pipeline development leveraging approved mAb targets
6-K
EX-99.1
SCNI
Scinai Immunotherapeutics Ltd
9 Jan 24
Report of Foreign Private Issuer
8:45am
aimed at predefined list of molecular targets. Designed to create significant clinical and commercial advantages. Scinai brings… MAX PLANCK , UMG … mammalian cells Quicker antibody discovery and optimization due to massive libraries De - risked pipeline development leveraging approved mAb targets
424B3
7y6d 8rivf2jhwt0
2 Jan 24
Prospectus supplement
8:24am
F-1/A
4kzolap3edn176
22 Dec 23
Registration statement (foreign) (amended)
9:11am
6-K
EX-99.2
4qzn197xdipd
14 Dec 23
Report of Foreign Private Issuer
6:21am
6-K
EX-99.1
8ae1szlwc alap79
14 Dec 23
Report of Foreign Private Issuer
6:21am
F-1
bw2vdfcofhef71kkjw
30 Oct 23
Registration statement (foreign)
4:59pm
424B5
3qxexzlu
19 Sep 23
Prospectus supplement for primary offering
10:03am
6-K
EX-99.1
9i8fneedijvbo3gagg
6 Sep 23
Report of Foreign Private Issuer
12:01pm
424B2
83t726dtqib uv
28 Aug 23
Prospectus for primary offering
4:01pm
6-K
EX-99.1
fclvp r9q0
23 Aug 23
Report of Foreign Private Issuer
6:10am
F-3
107k dlrqk
18 Aug 23
Shelf registration (foreign)
4:16pm
6-K/A
EX-99.1
wzz8og
18 Aug 23
Current report (foreign) (amended)
10:07am
6-K/A
EX-99.2
3u6dg8fo6
14 Aug 23
BiondVax Reports Second Quarter Financial Results and Provides Business Update
6:08am
6-K
EX-99.1
0w2iyu 5n13
12 Jul 23
Report of Foreign Private Issuer
12:00am
6-K
EX-99.1
i8792zqhcg4eo33ndq
5 Jul 23
Report of Foreign Private Issuer
9:28am
10-Q
atmpv3k
15 May 23
Quarterly report
4:49pm